G1 Therapeutics Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • G1 Therapeutics's estimated annual revenue is currently $42.2M per year.(i)
  • G1 Therapeutics received $47.0M in venture funding in May 2016.
  • G1 Therapeutics's estimated revenue per employee is $354,874
  • G1 Therapeutics's total funding is $497.3M.
  • G1 Therapeutics's current valuation is $429.9M. (January 2022)

Employee Data

  • G1 Therapeutics has 119 Employees.(i)
  • G1 Therapeutics grew their employee count by -37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company's pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 is based in Research Triangle Park, NC. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





G1 Therapeutics News

2022-04-20 - Zacks: Analysts Expect G1 Therapeutics, Inc. (NASDAQ:GTHX ...

G1 Therapeutics posted earnings of ($0.65) per share during the same quarter last year, which indicates a negative year over year growth rate of...

2022-04-20 - Zacks: Analysts Anticipate G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Post Earnings of -$0.99 Per Share

Equities research analysts expect that G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Rating) will post earnings per share of ($0.99) for the...

2022-04-19 - G1 Therapeutics: Needs To Expand Labels And Commercialize Better

Since my last five articles on G1 Therapeutics (NASDAQ:GTHX) over the last 24 months, the stock is down 84%, 58%, 72%, 59% and 56%...

2021-11-03 - G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights - Form 8-K

G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights - Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication ...

2021-10-01 - G1 Therapeutics : Announces Permanent J-Code from Centers for Medicare and Medicaid Services

RESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid Services (C ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

G1 Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$12.5MAMedImmune VenturesArticle
2016-05-13$47.0MCCormorant Asset ManagementArticle

G1 Therapeutics Executives

Jack BaileyChief Executive Officer
Mark AvaglianoChief Business Officer
Terry MurdockChief Operating Officer
Jennifer MosesChief Financial Officer
Scott WebbSenior Vice President, Technical Operations
Thomas AquilinaVice President, Pharmacovigilance
Marc ChiodaVice President, Medical Affairs
Yili PritchettVice President, Head of Biometrics
Jennifer WarnekeVice President Clinical Operations
Daniel RyanVice President, Program Management & Outsourcing
Will RobertsVice President, Corporate Communications and Investor Relations
Greg MaxfieldVP, Market Access
Chandra LovejoyVice President, Global Regulatory Affairs
David ElksVP, Information Technology
Yili PritchettSenior Vice President, Head of Biometrics